A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib
NCT00513253 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2015-02-16
Summary
This study is designed to estimate the relative bioavailability of alternative lapatinib oral formulations compared to the current tablet formulation.
Conditions
- Healthy Subjects
Interventions
- DRUG
-
lapatinib
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2008-05-31
- Completion
- 2008-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
NCT06435923 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
NCT01316848 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Food Effect Study of Two Formulations of TAK-906
NCT04831502 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension
NCT02641353 ·Status: COMPLETED ·Phase: PHASE1
-
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
NCT06048302 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants
NCT03978143 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation
NCT02006277 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers
NCT01125904 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
NCT05852340 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS
NCT02180503 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract
NCT01844323 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets
NCT05002231 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
NCT03280173 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants
NCT05123079 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
NCT05482308 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
NCT01208155 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
NCT05742594 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
NCT02034565 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
NCT04696393 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
NCT01209117 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets
NCT01387308 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
NCT02189330 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
NCT05287360 ·Status: COMPLETED ·Phase: PHASE1
-
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
NCT02792829 ·Status: COMPLETED ·Phase: PHASE1